Activist 13D/13G Filings - Theriva Biologics Inc. (TOVX)

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2022-02-23
4:42 pm
Sale
13GSYNTHETIC BIOLOGICS INC
SYN
Iroquois Capital Management LLC2,308,696
1.92%
-300,000decrease
(-11.50%)
View
2022-02-10
6:11 pm
Sale
13GSYNTHETIC BIOLOGICS INC NE
SYN
RENAISSANCE TECHNOLOGIES LLC20,600
0.02%
-1,217,133decrease
(-98.34%)
View
2022-02-04
4:23 pm
Purchase
13GSYNTHETIC BIOLOGICS INC NE
SYN
Hudson Bay Capital Management LP2,608,696
1.94%
389,677increase
(+17.56%)
View
2021-03-02
3:33 pm
Purchase
13DSYNTHETIC BIOLOGICS INC NE
SYN
Custodian Ventures LLC.2,224,500
2.1%
260,000increase
(+13.23%)
View
2021-02-22
09:45 am
Unchanged
13GSYNTHETIC BIOLOGICS INC
SYN
Iroquois Capital Management LLC2,608,696
9.99%
0
(Unchanged)
View
2021-02-10
5:48 pm
Purchase
13GSYNTHETIC BIOLOGICS INC NE
SYN
Hudson Bay Capital Management LP2,219,019
9.99%
722,464increase
(+48.28%)
View
2021-02-10
12:23 pm
Purchase
13GSYNTHETIC BIOLOGICS INC NE
SYN
RENAISSANCE TECHNOLOGIES LLC1,237,733
6.19%
1,237,733increase
(New Position)
View
2021-01-06
11:16 am
Purchase
13DSYNTHETIC BIOLOGICS INC NE
SYN
Custodian Ventures LLC.1,964,500
9.9%
1,964,500increase
(New Position)
View
2020-02-14
10:36 am
Unchanged
13GSYNTHETIC BIOLOGICS INC
SYN
Iroquois Capital Management LLC2,608,696
9.99%
0
(Unchanged)
View
2020-01-21
1:37 pm
Sale
13GSYNTHETIC BIOLOGICS INC NE
SYN
SABBY MANAGEMENT LLC838,641
11%
-278,818decrease
(-24.95%)
View